 |
Journal articles
APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures
Abstract : Hepatoblastoma (HB) is the most common liver cancer in children. We aimed to characterize HB related to APC (Adenomatous Polyposis Coli) germline mutation (APC-HB). This French multicentric retrospective study included 12 APC-HB patients under 5 at diagnosis. Clinical features of APC-HB were compared to the French SIOPEL2-3 cohort of HB patients. Molecular and histopathological analyses of APC-HB were compared to 15 consecutive sporadic HB treated at Bicêtre hospital from 2013 to 2015 (non-APC-HB). APC-HB patients have a peculiar spectrum of germline APC mutations, with no events in the main hotspot of classical APC mutations at codon 1309 (P < .05). Compared to sporadic HB, they have similar clinical features including good prognosis since all patients are alive in complete remission at last follow-up. APC-HB are mostly well-limited tumors with fetal predominance and few mesenchymal components. All APC-HB have an activated Wnt/β-catenin pathway without CTNNB1 mutation, confirming that germline APC and somatic CTNNB1 mutations are mutually exclusive (P < .001). Pathological reviewing identified massive intratumor tertiary lymphoid structures (TLS) containing both lymphocytes and antigen-presenting cells in all 11 APC-HB cases who received cisplatin-based neoadjuvant chemotherapy but not in five pre-chemotherapy samples (four paired biopsies and one patient resected without chemotherapy), indicating that these TLS are induced by chemotherapy (P < .001). Conclusion: APC-HB show a good prognosis, they are all infiltrated by cisplatin-induced TLS, a feature only retrieved in a minority of non-APC-HB. This suggests that APC inactivation can synergize with cisplatin to induce an immunogenic cell death that initiates an anti-tumor immune response.
Cited literature [42 references]
https://www.hal.inserm.fr/inserm-02346879
Contributor : Theo Hirsch Connect in order to contact the contributor
Submitted on : Tuesday, November 5, 2019 - 10:14:17 AM
Last modification on : Tuesday, October 19, 2021 - 4:10:19 PM
Long-term archiving on: : Thursday, February 6, 2020 - 3:16:11 PM
Contributor : Theo Hirsch Connect in order to contact the contributor
Submitted on : Tuesday, November 5, 2019 - 10:14:17 AM
Last modification on : Tuesday, October 19, 2021 - 4:10:19 PM
Long-term archiving on: : Thursday, February 6, 2020 - 3:16:11 PM
File
OncoimmunologyMorcrette2019.pd...
Publication funded by an institution